Bonesupport
259.4 SEK -4.28%7 investors are following this company
Bone Support is active in medical technology. The company develops and commercializes injectable bioceramic bone graft substitutes that are transformed into the patient's bone and have the ability to release drugs. The company's bone graft substitutes are based on the technology platform Cerament. At present, the company conducts ongoing clinical studies. The company has sales in Europe and North America and is headquartered in Lund, Sweden.
Revenue
591.08M
EBIT %
2.36 %
P/E
68.81
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BONEX
Daily low / high price
251.8 / 273.2
SEK
Market cap
17.3B SEK
Turnover
46.73M SEK
Volume
180K
Latest videos
Financial calendar
Interim report
11.07.2024
Interim report
24.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
HealthCap | 9.9 % | 10.0 % |
Swedbank Robur Fonder | 9.3 % | 9.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
BONESUPPORT™ APPOINTS ANNA STEGMARK EVP QM & RA
![Bonesupport, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/17a391ef-648a-4471-88f4-8591da40cce5.png)
Bonesupport, Audiocast with teleconference, Q2'24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
CERAMENT® contributes to fewer amputations – new data from Australia
BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 16 MAY 2024
Redeye: BONESUPPORT Q1 - Short-sighted reaction on solid report
![Bonesupport, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/de751c8e-5bdf-4e3d-ac34-1d789c06cb37.png)
Bonesupport, Audiocast with teleconference, Q1, 2024
BONESUPPORT HOLDING AB (publ) – publishes Q1 2024 Interim report
BONESUPPORT HOLDING AB PUBLISHES ANNUAL REPORT 2023
Redeye: BONESUPPORT - Leading an ongoing paradigm shift
BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim report Q1 2024
Notice of annual general meeting in BONESUPPORT HOLDING AB
CHANGE IN NUMBER OF SHARES AND VOTES IN BONESUPPORT HOLDING AB (PUBL)
CERAMENT® G RECEIVES FDA CLEARANCE FOR OPEN FRACTURES
BONESUPPORT has completed the issuance of series C shares
CERAMENT® BONE VOID FILLER RECEIVES FDA CLEARANCE FOR SPINAL INTERBODY FUSION PROCEDURES
The Board of Directors of BONESUPPORT has resolved on transfer of own shares and issue of series C shares
CHANGE IN THE MANAGEMENT TEAM
Redeye: BONESUPPORT Q4 - Uncalled share drop gives attractive entry points
![Bonesupport, Audiocast with teleconference, Year end report, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/5eb2a7a3-f4d7-4e1d-9eab-3c1f130d5c98.png)